Fig. 3.

Expression of α-Gal A in the livers of AAV2/8-hGLA–treated FD mice. FD mice were intravenously administered formulation buffer or the AAV2/8-hGLA at doses of 0.75E + 12, 1E + 12, 2.5E + 12, and 5E + 12 vg/kg, and tissues were collected at 12 weeks post-injection. A α-Gal A protein content in livers of FD mice treated with different doses of AAV2/8-hGLA was determined 12 weeks after administration; representative Western blot analyses are shown, and B relative gray value analyses were performed. C α-Gal A activity was determined in livers of AAV2/8-hGLA-treated FD mice. α-Gal A enzyme activity was measured using the α-Galactosidase (α-GAL) Activity Assay. Data are presented as the mean ± SEM (n = 6, 6, 6, 6, 4, for the FD, 0.75E + 12, 1E + 12, 2.5E + 12, and 5E + 12 vg/kg groups, respectively). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Unpaired t-tests was used to compare two groups of data